home / stock / eldn / eldn quote
Last: | $3.02 |
---|---|
Change Percent: | -1.07% |
Open: | $2.83 |
Close: | $3.02 |
High: | $3.2884 |
Low: | $2.83 |
Volume: | 609,149 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.02 | $2.83 | $3.02 | $3.2884 | $2.83 | 609,149 | 05-17-2024 |
$2.8 | $2.5 | $2.8 | $2.94 | $2.5 | 572,048 | 05-16-2024 |
$2.505 | $2.34 | $2.505 | $2.54 | $2.34 | 139,292 | 05-15-2024 |
$2.34 | $2.19 | $2.34 | $2.38 | $2.15 | 135,917 | 05-14-2024 |
$2.19 | $2.08 | $2.19 | $2.29 | $2 | 237,726 | 05-13-2024 |
$2.31 | $2.43 | $2.31 | $2.439 | $2.18 | 197,005 | 05-10-2024 |
$2.4 | $2.43 | $2.4 | $2.49 | $2.27 | 171,171 | 05-09-2024 |
$2.44 | $2.23 | $2.44 | $2.4806 | $2.23 | 394,113 | 05-08-2024 |
$2.26 | $2.15 | $2.26 | $2.29 | $2.11 | 2,532,836 | 05-07-2024 |
$2.44 | $2.5 | $2.44 | $2.5011 | $2.39 | 91,409 | 05-06-2024 |
$2.41 | $2.38 | $2.41 | $2.53 | $2.2816 | 178,489 | 05-03-2024 |
$2.3 | $2.38 | $2.3 | $2.3899 | $2.24 | 118,903 | 05-02-2024 |
$2.29 | $2.43 | $2.29 | $2.43 | $2.1261 | 146,819 | 05-01-2024 |
$2.39 | $2.38 | $2.39 | $2.4 | $2.29 | 92,569 | 04-30-2024 |
$2.37 | $2.07 | $2.37 | $2.43 | $2.0501 | 321,755 | 04-29-2024 |
$2.06 | $2.05 | $2.06 | $2.08 | $2 | 81,544 | 04-26-2024 |
$2.02 | $1.97 | $2.02 | $2.1 | $1.91 | 67,382 | 04-25-2024 |
$1.97 | $2.18 | $1.97 | $2.2 | $1.96 | 100,706 | 04-24-2024 |
$2.16 | $2.01 | $2.16 | $2.2 | $1.99 | 189,917 | 04-23-2024 |
$2.02 | $2 | $2.02 | $2.2 | $1.92 | 313,628 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will pa...
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phas...